Stay updated on Fostamatinib in Warm Autoimmune Hemolytic Anemia Clinical Trial

Sign up to get notified when there's something new on the Fostamatinib in Warm Autoimmune Hemolytic Anemia Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Fostamatinib in Warm Autoimmune Hemolytic Anemia Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the context of a Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia, focusing on evaluating the long-term safety of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia.
    Difference
    0.1%
    Check dated 2024-06-06T14:38:56.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying the need for written informed consent and completion of a prior study phase. Previously, no information was provided in this section.
    Difference
    9%
    Check dated 2024-05-22T21:12:28.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:43:28.000Z thumbnail image

Stay in the know with updates to Fostamatinib in Warm Autoimmune Hemolytic Anemia Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Fostamatinib in Warm Autoimmune Hemolytic Anemia Clinical Trial page.